Speaker illustration

Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Society of Cardiology
Heart Failure Association

Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, where she is deputy head of Center and deputy clinical lead. She obtained her Medical degree (MD) and qualifications as a cardiologist at the University of Pisa. She was appointed Director of the UCL CMR unit at the RFH in 2015, which she founded, and Professor of Cardiology at UCL in 2020. She was awarded with an intermediate fellowship from the British Heart Foundation in 2018. She is the recipient of numerous awards, including the Michael Davies Early Career Award in 2021 and the BHF Fellow of the year award in 2022. Her major clinical and research interests are in the delivery of efficient and effective care for patients with amyloidosis, with a particular focus on new technologies: imaging and drugs.

How to manage cardiac amyloidosis

Event: Heart Failure 2023

Topic: Pharmacology and Pharmacotherapy

Session type: Symposium


Valvular heart disease 2

Event: Heart Failure 2023

Topic: Valvular Heart Disease

Session type: Clinical Cases


Translating science into practice

Event: Heart Failure 2023

Topic: Cardiovascular Disease in Special Populations

Session type: Satellite Symposium


Hereditary transthyretin (ATTRv) amyloidosis: multi-modality imaging for a multisystem disease

Event: EACVI 2023

Topic: Cross-Modality and Multi-Modality Imaging Topics

Session type: Satellite Symposium


Imaging insight into Covid myocarditis and long Covid

Event: ESC Congress 2022

Topic: Myocardial Disease

Session type: Moderated ePosters


Oral abstract session 3

Event: EuroCMR 2017

Topic: Cardiac Magnetic Resonance

Session type: Abstract Sessions


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb